Leveraging Tubulin Isotype Structural Differences to Design Less Hematotoxic β5 Selective Covalent Inhibitors for...

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Current microtubule-targeting agents (MTAs) for cancer treatment often cause significant hematotoxicity and multidrug resistance (MDR).
• The colchicine binding site in β-5 tubulin contains Cys-239, while β-1 tubulin has Ser-239, offering a basis for selective covalent inhibition.
• Exploiting reactivity differences between cysteine and serine residues can lead to targeted drug design.

Purpose of the Study:

• To discover and design novel β-5 tubulin-specific covalent inhibitors for non-small cell lung cancer (NSCLC).
• To develop therapeutic agents that minimize hematotoxicity, a major dose-limiting side effect of existing microtubule-targeting agents.
• To achieve selective inhibition of β-5 tubulin over β-1 tubulin.

Main Methods:

• Development of β-5 and β-1 tubulin models for computational studies.
• Covalent docking and virtual screening to identify potential inhibitors targeting the β-5 tubulin colchicine binding site.
• Comparative analysis of inhibitor selectivity and binding affinity for β-5 versus β-1 tubulin, including molecular dynamics simulations.

Main Results:

• Identification of 20 potential inhibitor compounds through virtual screening.
• Four compounds demonstrated selective inhibition of β-5 tubulin with higher binding affinity compared to β-1 tubulin.
• Molecular dynamics studies confirmed the stability and enhanced binding of these selective inhibitors.

Conclusions:

• Four novel β-5 tubulin-specific covalent inhibitors were identified as potential therapeutic agents for NSCLC.
• These inhibitors offer a promising strategy for reducing hematotoxicity associated with microtubule-targeting therapies.
• Selective tubulin inhibition represents a critical advancement for improving cancer treatment efficacy and patient safety.